Dr. Chakra P. Chaulagain, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 23
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 235
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
FL license ME 119743
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Cleveland Clinic Cleveland, OH
- Cleveland Clinic Hospital Weston, FL
Medical groups
- Cleveland Clinic Florida A Nonprofit Corporation (735 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 235
- Services billed
- 975
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 20,700 | 26 |
| Established patient office or other outpatient visit, 40-54 minutes | 315 | 120 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 151 | 31 |
| Established patient office or other outpatient visit, 30-39 minutes | 148 | 116 |
| Injection, zoledronic acid, 1 mg | 102 | 13 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 73 | 23 |
| Administration of chemotherapy into vein, 1 hour or less | 57 | 13 |
| Injection of drug or substance under skin or into muscle | 48 | 16 |
| Injection of additional new drug or substance into vein | 44 | 14 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 43 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Revlimid (lenalidomide) | 214 |
| Lenalidomide | 71 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Weston, FL | 60 |
| Brukinsa (zanubrutinib) | 60 |
| Hydroxyurea Other prescribers in Weston, FL | 57 |
| Acyclovir Other prescribers in Weston, FL | 53 |
| Jakafi (ruxolitinib phosphate) | 49 |
| Venclexta (venetoclax) | 39 |
| Pomalyst (pomalidomide) | 37 |
| Clonazepam Other prescribers in Weston, FL | 35 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 21 companies reported 107 payments worth $44,223 in total to this clinician.
| Janssen Biotech, Inc. | $18,296 |
|---|---|
| Regeneron Healthcare Solutions, Inc. | $14,801 |
| E.r. Squibb & Sons, L.l.c. | $4,476 |
| Geron Corporation | $3,381 |
| Janssen Scientific Affairs, LLC | $2,200 |
| GlaxoSmithKline, LLC. | $285 |
| Genzyme Corporation | $122 |
| Pfizer Inc. | $118 |
| Compensation for services other than consulting (speaking, faculty) | $30,599 |
|---|---|
| Consulting Fee | $9,838 |
| Food and Beverage | $2,326 |
| Travel and Lodging | $1,336 |
| Education | $125 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. Oct 21, 2025 | Compensation for services other than consulting (speaking, faculty) LYNOZYFIC · HEMATOLOGY AND ONCOLOGY | $4,704 |
| Regeneron Healthcare Solutions, Inc. Nov 25, 2025 | Compensation for services other than consulting (speaking, faculty) LYNOZYFIC · HEMATOLOGY AND ONCOLOGY | $4,704 |
| Janssen Biotech, Inc. Jul 23, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $4,163 |
| Janssen Biotech, Inc. Jul 23, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $4,163 |
| Janssen Biotech, Inc. Aug 15, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $4,163 |
| Janssen Biotech, Inc. May 5, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $3,608 |
| Geron Corporation Dec 4, 2025 | Consulting Fee IMETELSTAT · HEMATOLOGY | $3,200 |
| E.r. Squibb & Sons, L.l.c. Nov 13, 2025 | Consulting Fee | $2,308 |
| E.r. Squibb & Sons, L.l.c. Nov 19, 2025 | Consulting Fee | $2,130 |
| Regeneron Healthcare Solutions, Inc. Oct 24, 2025 | Compensation for services other than consulting (speaking, faculty) LYNOZYFIC · HEMATOLOGY AND ONCOLOGY | $1,960 |
All 33 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Geron Corporation Dec 4, 2025 | Consulting Fee IMETELSTAT · HEMATOLOGY | $3,200 |
| Geron Corporation Dec 4, 2025 | Travel and Lodging IMETELSTAT · HEMATOLOGY · travel to MIAMI, FL | $47.54 |
| Regeneron Healthcare Solutions, Inc. Nov 25, 2025 | Compensation for services other than consulting (speaking, faculty) LYNOZYFIC · HEMATOLOGY AND ONCOLOGY | $4,704 |
| E.r. Squibb & Sons, L.l.c. Nov 19, 2025 | Consulting Fee | $2,130 |
| E.r. Squibb & Sons, L.l.c. Nov 13, 2025 | Consulting Fee | $2,308 |
| Regeneron Healthcare Solutions, Inc. Oct 31, 2025 | Travel and Lodging LYNOZYFIC · HEMATOLOGY AND ONCOLOGY · travel to MIAMI, FL · in-kind | $44.80 |
| Regeneron Healthcare Solutions, Inc. Oct 31, 2025 | Travel and Lodging LYNOZYFIC · HEMATOLOGY AND ONCOLOGY · travel to MIAMI, FL · in-kind | $5.80 |
| Regeneron Healthcare Solutions, Inc. Oct 28, 2025 | Compensation for services other than consulting (speaking, faculty) LYNOZYFIC · HEMATOLOGY AND ONCOLOGY | $1,960 |
| Regeneron Healthcare Solutions, Inc. Oct 24, 2025 | Compensation for services other than consulting (speaking, faculty) LYNOZYFIC · HEMATOLOGY AND ONCOLOGY | $1,960 |
| Regeneron Healthcare Solutions, Inc. Oct 21, 2025 | Compensation for services other than consulting (speaking, faculty) LYNOZYFIC · HEMATOLOGY AND ONCOLOGY | $4,704 |
| Janssen Scientific Affairs, LLC Sep 18, 2025 | Consulting Fee DARZALEX · Oncology | $1,320 |
| Janssen Pharmaceuticals, Inc Sep 16, 2025 | Education in-kind | $15.99 |
| Janssen Pharmaceuticals, Inc Sep 16, 2025 | Education in-kind | $8.24 |
| Janssen Biotech, Inc. Sep 10, 2025 | Travel and Lodging RYBREVANT; CARVYKTI · Oncology · travel to Vero Beach, FL | $165 |
| Janssen Biotech, Inc. Sep 10, 2025 | Travel and Lodging RYBREVANT; CARVYKTI · Oncology · travel to Vero Beach, FL | $16.42 |
| Regeneron Healthcare Solutions, Inc. Aug 26, 2025 | Compensation for services other than consulting (speaking, faculty) LYNOZYFIC · HEMATOLOGY AND ONCOLOGY | $1,176 |
| Janssen Biotech, Inc. Aug 15, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $4,163 |
| Janssen Biotech, Inc. Aug 6, 2025 | Travel and Lodging RYBREVANT; CARVYKTI · Oncology · travel to Tampa, FL | $356 |
| Janssen Biotech, Inc. Aug 6, 2025 | Travel and Lodging RYBREVANT; CARVYKTI · Oncology · travel to Tampa, FL | $20.00 |
| Janssen Biotech, Inc. Aug 6, 2025 | Travel and Lodging RYBREVANT; CARVYKTI · Oncology · travel to Tampa, FL | $8.08 |
| Janssen Biotech, Inc. Jul 25, 2025 | Travel and Lodging RYBREVANT; CARVYKTI · Oncology · travel to Naples, FL | $174 |
| Janssen Biotech, Inc. Jul 25, 2025 | Travel and Lodging RYBREVANT; CARVYKTI · Oncology · travel to Naples, FL | $28.62 |
| Janssen Biotech, Inc. Jul 23, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $4,163 |
| Janssen Biotech, Inc. Jul 23, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $4,163 |
| Janssen Biotech, Inc. Jul 17, 2025 | Travel and Lodging RYBREVANT; CARVYKTI · Oncology · travel to Tampa, FL · in-kind | $192 |
| Janssen Biotech, Inc. Jul 11, 2025 | Travel and Lodging RYBREVANT; CARVYKTI · Oncology · travel to Naples, FL · in-kind | $234 |
| Janssen Biotech, Inc. Jun 26, 2025 | Travel and Lodging RYBREVANT; CARVYKTI · Oncology · travel to Tampa, FL · in-kind | $5.50 |
| Janssen Biotech, Inc. Jun 18, 2025 | Travel and Lodging RYBREVANT; CARVYKTI · Oncology · travel to Naples, FL · in-kind | $5.50 |
| Janssen Scientific Affairs, LLC May 27, 2025 | Consulting Fee | $880 |
| Janssen Biotech, Inc. May 14, 2025 | Travel and Lodging RYBREVANT; CARVYKTI · Oncology · travel to Fort Lauderdale, FL | $32.90 |
| Janssen Biotech, Inc. May 5, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $3,608 |
| Janssen Biotech, Inc. Mar 24, 2025 | Education DARZALEX; TALVEY; TECVAYLI · Oncology · in-kind | $83.99 |
| Pfizer Inc. Feb 19, 2025 | Education ELREXFIO · ONCOLOGY · in-kind | $17.16 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 16 industry-funded studies in 2025, from 6 companies. The companies reported $941,664 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple …
Janssen Research & Development, LLC - A Phase 1 Randomized, Open-Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma
Janssen Research & Development, LLC - A Phase 3, Double Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia in Treatment Naive Patients with Stage IIIa AL Ca…
Alexion Pharmaceuticals, Inc. - A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refract…
Celgene Corporation - A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with …
Celgene Corporation - A Phase 3, Double Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment Naive Patients with Stage IIIb AL Cardi…
Alexion Pharmaceuticals, Inc. - A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Beone Medicines Ltd. · Recruiting · NCT06742996 - A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously …
Celgene Corporation - A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple …
Janssen Research & Development, LLC - A study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1)
E.r. Squibb & Sons, L.l.c.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.